Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ASNS
CUSIPN/A
Phone781-819-5704
Debt
Debt-to-Equity Ratio0.20
Current Ratio7.38
Quick Ratio7.38
Price-To-Earnings
Trailing P/E Ratio-1.17
Forward P/E Ratio-4.16
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.29 per share
Price / Book4.41
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees40
Outstanding Shares14,290,000
Arsanis (NASDAQ:ASNS) Frequently Asked Questions
What is Arsanis' stock symbol?
Arsanis trades on the NASDAQ under the ticker symbol "ASNS."
How were Arsanis' earnings last quarter?
Arsanis Inc (NASDAQ:ASNS) announced its earnings results on Thursday, May, 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.30. View Arsanis' Earnings History.
What price target have analysts set for ASNS?
4 brokers have issued twelve-month target prices for Arsanis' shares. Their predictions range from $23.00 to $27.00. On average, they anticipate Arsanis' stock price to reach $25.3333 in the next twelve months. View Analyst Ratings for Arsanis.
Who are some of Arsanis' key competitors?
Some companies that are related to Arsanis include BAVARIAN NORDIC/S (BVNRY), La Jolla Pharmaceutical (LJPC), Heska (HSKA), Fate Therapeutics (FATE), Voyager Therapeutics (VYGR), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Scholar Rock (SRRK), Mesoblast (MESO), CASI Pharmaceuticals (CASI), Nightstar Therapeutics (NITE), Surface Oncology (SURF), Vericel (VCEL), MeiraGTx (MGTX) and PDL BioPharma (PDLI).
Who are Arsanis' key executives?
Arsanis' management team includes the folowing people:
- Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 54)
- Dr. René Russo, Pres, CEO & Director (Age 43)
- Mr. Michael P. Gray MBA, CPA, COO & CFO (Age 47)
- Dr. Anthony Christopher Stevens, Chief Medical Officer (Age 59)
- Dr. Eszter Nagy, Co-Founder (Age 52)
When did Arsanis IPO?
(ASNS) raised $50 million in an initial public offering on Thursday, November 16th 2017. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Citigroup, Cowen and Piper Jaffray acted as the underwriters for the IPO.
When did Arsanis' lock-up period expire?
Arsanis' lock-up period expired on Tuesday, May 15th. Arsanis had issued 4,000,000 shares in its initial public offering on November 16th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. Since the expiration of Arsanis' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Has Arsanis been receiving favorable news coverage?
Media stories about ASNS stock have trended positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arsanis earned a daily sentiment score of 0.37 on Accern's scale. They also assigned press coverage about the company an impact score of 46.89 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Arsanis' major shareholders?
Arsanis' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (1.73%), BlackRock Inc. (1.23%), First Eagle Investment Management LLC (0.87%), Sphera Funds Management LTD. (0.80%), Northern Trust Corp (0.22%) and Schwab Charles Investment Management Inc. (0.06%). Company insiders that own Arsanis stock include Polaris Venture Management Co and Tillman U Gerngross. View Institutional Ownership Trends for Arsanis.
Which major investors are selling Arsanis stock?
Which major investors are buying Arsanis stock?
ASNS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., First Eagle Investment Management LLC, Northern Trust Corp, JPMorgan Chase & Co., Schwab Charles Investment Management Inc., California State Teachers Retirement System and New York State Common Retirement Fund. Company insiders that have bought Arsanis stock in the last two years include Polaris Venture Management Co and Tillman U Gerngross. View Insider Buying and Selling for Arsanis.
How do I buy shares of Arsanis?
Shares of ASNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arsanis' stock price today?
One share of ASNS stock can currently be purchased for approximately $18.94.
How big of a company is Arsanis?
Arsanis has a market capitalization of $241.15 million. The company earns $-33,870,000.00 in net income (profit) each year or ($16.23) on an earnings per share basis. Arsanis employs 40 workers across the globe.
How can I contact Arsanis?
Arsanis' mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The company can be reached via phone at 781-819-5704 or via email at [email protected]
MarketBeat Community Rating for Arsanis (ASNS)
MarketBeat's community ratings are surveys of what our community members think about Arsanis and other stocks. Vote "Outperform" if you believe ASNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
